Story perspectives

FDA Approves Two New Drugs for Drug-Resistant Gonorrhoea

1/1/2026

38 8

Summary

Story summary

The U.S. Food and Drug Administration approved two drugs, Zoliflodacin and Gepotidacin, to treat drug-resistant gonorrhoea.
Gonorrhoea infections exceed 82 million annually, with especially high rates in Africa and the Western Pacific.
In England, cases reached a record high as drug resistance to key antibiotics surged.
Zoliflodacin, developed through a non-profit initiative, showed over 90% efficacy in curing genital gonorrhoea in trials involving 930 participants across multiple countries.

1 of 1

Story summary

The U.S. Food and Drug Administration approved two drugs, Zoliflodacin and Gepotidacin, to treat drug-resistant gonorrhoea.
Gonorrhoea infections exceed 82 million annually, with especially high rates in Africa and the Western Pacific.
In England, cases reached a record high as drug resistance to key antibiotics surged.
Zoliflodacin, developed through a non-profit initiative, showed over 90% efficacy in curing genital gonorrhoea in trials involving 930 participants across multiple countries.